ZSTK3744
ZSTK3744 is an aryl hydrocarbon receptor (AhR) agonist. ZSTK3744 directly binds to AhR, upregulates the expression of AhR target genes including CYP1A1, CYP1B1 and TIPARP, and mediates cell growth inhibitory activity in triple-negative breast cancer cells. ZSTK3744 induces apoptosis in triple-negative breast cancer cells. ZSTK3744 exhibits anti-tumor activity and can be used in the research of chemoresistant triple-negative breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 3106975-38-3
- Formula: C22H19N7
- Molecular Weight:381.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
ZSTK3744 (0.1-1000 nM; 72 h) (compound 12) potently inhibits the growth of MDA-MB-468 triple-negative breast cancer (TNBC) cells, with an IC50 of 0.87 nM[1].
ZSTK3744 (0.1-1000 nM; 72 h) potently inhibits the growth of Doxorubicin (HY-15142A)-resistant MDA-MB-468/AR triple-negative breast cancer (TNBC) cells, with an IC50 of 0.92 nM[1].
ZSTK3744 (0.1-1000 nM; 72 h) inhibits the growth of Paclitaxel (HY-B0015)-resistant MDA-MB-468/PR triple-negative breast cancer (TNBC) cells with an IC50 of 23.54 nM[1].
ZSTK3744 (1-24 h) upregulates the mRNA expression of CYP1A1 and TIPARP in MDA-MB-468 triple-negative breast cancer (TNBC) cells in a time-dependent manner, with significant induction observable as early as 1 hour after treatment[1].
ZSTK3744 (24 h) induces apoptosis in MDA-MB-468 TNBC cells, and its cell growth inhibitory activity is mediated at least partially via the caspase-dependent apoptotic pathway[1].
ZSTK3744 (0.1-1000 nM; 72 h) potently inhibits the growth of MDA-MB-453 triple-negative breast cancer (TNBC) cells, with an IC50 of 1.14 nM[1].
ZSTK3744 (0.1-1000 nM; 72 h) potently inhibits the growth of DU4475 triple-negative breast cancer (TNBC) cells, with an IC50 of less than 0.50 nM[1].
ZSTK3744 (0.1-1000 nM; 72 h) exerts no significant inhibitory effect on the growth of Hs578T TNBC cells, with an IC50 >500 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-453 TNBC cells
-
Concentration:0.1, 1, 10, 100 and 10,000 nM
-
Incubation Time:72 h
-
Result:Inhibited cell growth with an IC50 of 1.14 nM.
ZSTK3744 (1-5 mg/kg; i.v.; on days 0, 4, and 8) inhibits tumor growth in parental triple-negative breast cancer (TNBC) mouse xenograft models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.CB17-Prkdcscid/J (NOD/SCID) (female, 6 weeks old, subcutaneous xenograft of Doxorubicin-resistant MDA-MB-468 cells)[1]
-
Dosage:2.5 mg/kg; 10 mg/kg
-
Administration:i.v.; on days 0, 7, and 14
-
Result:Inhibited tumor growth in a dose-dependent manner.
Reduced tumor volume significantly compared with the vehicle-treated group and the eribulin-treated group.
-
Animal Model:NOD.CB17-Prkdcscid/J (NOD/SCID) (female, 6 weeks old, subcutaneous xenograft of parental MDA-MB-468 cells)[1]
-
Dosage:1 mg/kg; 2.5 mg/kg; 5 mg/kg
-
Administration:i.v.; on days 0, 4, and 8
-
Result:Reduced tumor volume at 2.5 and 5 mg/kg.
Reduced tumor volume relative to the vehicle-treated group at all tested doses, with the highest dose showing the greatest inhibition.
Chemical Information
-
CAS No. 3106975-38-3
-
Molecular Weight 381.43
-
Formula C22H19N7
-
SMILES
CC1=CC=CC2=C1N=CN2C3=NC(C4=CC(CCN5)=C5N=C4)=C(C=CN6C)C6=N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz